The appointment might raise some eyebrows given Roche's need to drive pharma sales as it copes with the loss of patent protection on an earlier generation of antibody-based therapies – now being ...

Last year, Boehringer’s human pharma sales grew more than 10% to €20.8 billion, driven by Jardianc,e which grew by nearly a third on the back of its recent CKD approval as well as pulmonary ...